Home Financial Markets Is That why NantKwest (NK) stock soared in the late hours last...

Is That why NantKwest (NK) stock soared in the late hours last night?

‎NantKwest (NASDAQ: NK) stock surged 23.14%  to $18.2 in the extended hour’s section. Before that during the regular session stock was down -7.57% to close at $14.78. NK shares price is currently trading at a distance of 37.21% from its 50-days Simple Moving Average.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. ‎‎

Company Intro


The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


An innovative, clinical-stage, immunotherapy company, NantKwest (NASDAQ: NK) harnesses the innate immune system’s power to treat cancer and infectious diseases. NK Cells NantKwest is the leader in producing clinical dose natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancerous cells as well as virally-infected cells.

Read More

What happened lately… 

NantKwest, Inc. (NASDAQ: NK), a leading company in cellular medicines, and ImmunityBio, Inc., which is a privately held immunotherapy company revealed that the median survival rates for patients with advanced metastatic pancreatic cancer which is currently untreated have more than doubled compared to historical survival rates.

PD L1 t-haNK protocol data from NantKwest, Inc. (NASDAQ: NK) shows median survival rates more than doubled those of patients with advanced metastatic pancreatic cancer for which no FDA-approved treatment exists. These trials, derived from the original Cancer Moonshot hypothesis and the exploratory QUILT trials in 2017, suggest that survival rates can be improved by orchestrating natural killer and T-cell therapy without high-dose chemotherapy.

Early Cancer Moonshot trials combined cell therapy and immunotherapy from several companies, including ImmunityBio, NantKwest, Celgene, and Pfizer. The problem explored the hypothesis that cancer cells could be eradicated by activating the patient’s immune system rather than high-dose chemotherapy. In multiple QUILT clinical trials investigating the combination of cell therapy, immunostimulating antibodies, adenovirus-based cancer vaccines, and low-dose chemotherapy between 2017 and 2020, preliminary results have proved the median survival rate for patients with metastatic pancreatic cancer can increase threefold. Based on data from these trials, ImmunityBio is conducting a three-cohort pivotal trial (QUILT 88) in metastatic pancreatic cancer.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

Summary

Analysts may see many potentials in the biotech stocks but failing clinical trials could happen if the biotechs do well in tests. There are risks associated with investing in biotech stocks, including companies running out of money and needing to pay for clinical studies, complete regulatory filings, and bring new drugs to market.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Apple Inc. (AAPL) Stocks dip but future prospects for the company seem very positive

On Thursday, Apple shares (NASDAQ: AAPL) closed at $120.99 which is 3.5% lower. In the after-hours session, the price further declined by 0.2%.  The...

Tesla Inc. (TSLA): a Game of Thrones, Tweets and Bitcoin

Tesla Inc. (NASDAQ: TSLA) shares plunged by more than 8% when the market closed on Thursday. The news that most significantly impacted this plunge...

The Reasons Behind 30% Fall Of Tricida, Inc.’s (TCDA) Shares In Extended Trades

The drugmaker Tricida, Inc.’s (TCDA) shares experienced a fall of -29.62% in the trading after the ring of the bell on Thursday. The South...

Why Chromadex Corp. (CDXC) Remains A Gainer After Ring Of The Bell?

The biotechnology company ChromaDex Corporation (CDXC) continued the rally after ring of the bell on Thursday rising +18.68%. During the regular session price of...

ReTo Eco-Solutions Stock Drops Pre-Market Today: Why?

The manufacturer and distributor of construction material ReTo Eco-Solutions Inc. (NASDAQ: RETO) has been experiencing a fall of more than 10% in pre-market session...

What Caused Amneal Pharmaceuticals (AMRX) To Rise 4% After-Hours On Friday? – Here Is An Explanation

Shares of fully integrated pharmaceutical company Amneal Pharmaceuticals Inc (AMRX) raised +3.9% on Friday after ring of the bell. The new came on the...

Why Atlas Crest Investment (ACIC) Stock Has Risen 9% After-Hour On Friday?

Atlas Crest Investment Corporation (NYSE: ACIC) stock came rising +8.91 to $12.96 in after-hour trading on Friday. The company saw its price falling -2.14%...

Were You Wondering Why Northern Dynasty (NAK) Stock Spiked 24% In Early Trades Today?

Shares of mineral exploration firm Northern Dynasty Minerals Ltd. (NYSE: NAK) has been gaining momentum in early trades today. As of 11:42 a.m. EST,...

Related News

What Took Gabelli Healthcare (GRX) Stock Down 18% In Pre-Market?

The Gabelli Healthcare & Wellness Trust (GRX) is sinking -18.33% in pre-market trading today following the announcement of a cash distribution by the organization...

In Premarket, What Has Been Causing AmeriServ Financial (ASRV) Stock To Increase 100%?

AmeriServ Financial, Inc. (NASDAQ: ASRV) has been seeing price of its share rising more than 100% in pre-market session today. The holding firm of...

You Should Read THIS Before Investing In Hut 8 Mining Corp’s Ordinary Shares (OTC: HUTMF)

Hut 8 Mining Corp - Ordinary Shares (OTC-HUTMF) stock soared by 21.74% in the last trading session, reaching $10.390. Over the last month, the...

Fluidigm Corporation (FLDM): Why The Stock Is Declining In Premarket Trading Today

Shares of Fluidigm Corporation (NASDAQ: FLDM) have been plummeting -14.10% to $6.09 in the pre-market session today. The company which provides innovative biotechnology tools...

This Is Why Recon Technology, Ltd. (RCON) Just Got Our Attention

Recon Technology, Ltd. (RCON) ended Monday 12% higher thanks to news that it has raised equity ownership in FGS to 51%. The better news...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Insider Watchlist

Important Earnings

We do not sell or share your information with anyone.